Frontier IP narrows losses and cuts costs as portfolio delivers technical and funding gains

Frontier IP Group (LSE:FIPP) reported an unaudited pre-tax loss of £3.1 million for the six months to 31 December 2025. The result was largely influenced by non-cash IFRS 16 lease accounting charges related to its SC2 innovation hub and a downward fair-value adjustment in one of its portfolio companies. Operating costs were reduced to £1.6 million following a series of cost rationalisation measures, and the group has outlined plans to implement additional savings of around £1 million annually from May 2026 as it tightens financial discipline amid challenging conditions in AIM-listed and early-stage technology markets.

During the period, the company raised £0.9 million through equity issuances—below its original target—and is now seeking further funding through a combination of equity and debt. Net assets per share declined to 52.7p, while cash balances fell to £1.6 million. Despite these financial pressures, several portfolio companies achieved important technical, commercial and funding milestones. These included significant fundraising rounds and international agreements for Pulsiv, Alusid and Amprologix, promising vaccine trial progress at The Vaccine Group, and continued strategic development at companies such as 2D Photonics and GraphEnergyTech. These developments support Frontier IP’s longer-term strategy of building value through the commercialisation of early-stage technologies.

The company’s outlook remains constrained by recurring losses, continued cash outflows and increased leverage introduced in 2025. Technical indicators also remain weak, with the share price trading well below key moving averages and showing negative MACD momentum. Valuation metrics provide limited support due to a negative price-to-earnings ratio and the absence of dividend yield data.

More about Frontier IP

Frontier IP Group is a UK-based company focused on commercialising intellectual property by creating and scaling spin-out businesses from universities and industry research. The group collaborates with academic institutions, investors and corporate partners to develop early-stage technology ventures across areas including advanced materials, clean technology, digital solutions and life sciences. Its strategy centres on building value in these companies as they mature toward potential commercial success and exit opportunities.